323 related articles for article (PubMed ID: 35616289)
21. Tamoxifen as a modulator of CXCL12-CXCR4-CXCR7 chemokine axis: A breast cancer and glioblastoma view.
Gonçalves TL; de Araújo LP; Pereira Ferrer V
Cytokine; 2023 Oct; 170():156344. PubMed ID: 37639844
[TBL] [Abstract][Full Text] [Related]
22. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy.
Gregory JV; Kadiyala P; Doherty R; Cadena M; Habeel S; Ruoslahti E; Lowenstein PR; Castro MG; Lahann J
Nat Commun; 2020 Nov; 11(1):5687. PubMed ID: 33173024
[TBL] [Abstract][Full Text] [Related]
23. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
24. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
25. CXCL12-induced upregulation of FOXM1 expression promotes human glioblastoma cell invasion.
Wang S; Zhang S; Li J; Xu X; Weng Y; Zheng M; Ouyang L; Li F
Biochem Biophys Res Commun; 2014 Apr; 447(1):1-6. PubMed ID: 24561124
[TBL] [Abstract][Full Text] [Related]
26. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
27. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
28. Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells.
Liu C; Pham K; Luo D; Reynolds BA; Hothi P; Foltz G; Harrison JK
PLoS One; 2013; 8(3):e59750. PubMed ID: 23555768
[TBL] [Abstract][Full Text] [Related]
29. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
Ping YF; Yao XH; Jiang JY; Zhao LT; Yu SC; Jiang T; Lin MC; Chen JH; Wang B; Zhang R; Cui YH; Qian C; Wang Jm; Bian XW
J Pathol; 2011 Jul; 224(3):344-54. PubMed ID: 21618540
[TBL] [Abstract][Full Text] [Related]
30. Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy.
Fan Q; Kuang L; Wang B; Yin Y; Dong Z; Tian N; Wang J; Yin T; Wang Y
ACS Nano; 2024 Jun; 18(22):14469-14486. PubMed ID: 38770948
[TBL] [Abstract][Full Text] [Related]
31. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
[TBL] [Abstract][Full Text] [Related]
32. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
33. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
35. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.
Sarchio SNE; Scolyer RA; Beaugie C; McDonald D; Marsh-Wakefield F; Halliday GM; Byrne SN
J Invest Dermatol; 2014 Apr; 134(4):1091-1100. PubMed ID: 24226205
[TBL] [Abstract][Full Text] [Related]
37. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
Lu G; Qiu Y; Su X
Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
[TBL] [Abstract][Full Text] [Related]
38. SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy.
Jiang K; Li J; Zhang J; Wang L; Zhang Q; Ge J; Guo Y; Wang B; Huang Y; Yang T; Hao D; Shan L
Int Immunopharmacol; 2019 Oct; 75():105818. PubMed ID: 31437795
[TBL] [Abstract][Full Text] [Related]
39. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
40. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Redjal N; Chan JA; Segal RA; Kung AL
Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
